ZR8.F ONCODES.PREC.MED. EO-34
- Market cap
- EUR 4.63M
- P/E
- -
- P/B
- 1.13x
- ROE
- 10.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ZR8.F undervalued?
Graham numberThe Graham number of ONCODES.PREC.MED. EO-34 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ONCODES.PREC.MED. EO-34 fundamental analysis
No fundamental analysis for ONCODES.PREC.MED. EO-34 yet.
ONCODES.PREC.MED. EO-34 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced…
Full company profileONCODES.PREC.MED. EO-34 financial statements
ONCODES.PREC.MED. EO-34 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.83M | 7.98M | 1.07M | 207K | 261K |
| Gross Profit | -1.98M | 460K | -6.60M | -6.29M | 9.73M |
| Operating Income | -3.73M | -1.61M | -9.94M | -7.81M | 8.22M |
| EBITDA | - | -1.44M | -9.46M | -7.26M | 6.06M |
| Net Income | -2.94M | -231K | -8.09M | -7.21M | 5.48M |
| EPS | -0.43 | -0.01 | -0.49 | -0.40 | 0.30 |
| Balance Sheet | |||||
| Total Assets | 8.37M | 18.4M | 16.6M | 10.7M | 15.0M |
| Total Liabilities | 4.17M | 6.59M | 12.9M | 11.1M | -37.9M |
| Shareholders' Equity | 4.20M | 11.8M | 3.69M | -429K | 52.9M |
| Cash & Short-term Investments | 4.92M | 13.4M | 323K | 437K | 312K |
| Cash Flow | |||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ratios | |||||
| ROE | -70.1% | -2.0% | -219.2% | - | 10.4% |
| ROA | -35.2% | -1.3% | -48.6% | -67.3% | 36.6% |
| Net Profit Margin | -76.9% | -2.9% | -754.6% | -3,482.2% | 2,098.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ONCODES.PREC.MED. EO-34 dividends
ONCODES.PREC.MED. EO-34 has not paid dividends in the last 5 fiscal years.
Who owns ONCODES.PREC.MED. EO-34
- Insiders 57.11%
- Institutions 0.00%
- Public & others 42.89%
- Shares outstanding 19.1M
- Free float 17.4M
ONCODES.PREC.MED. EO-34 company profile
- Company name
- ONCODES.PREC.MED. EO-34
- Ticker
- ZR8.F
- ISIN
- FR001400CM63
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 18 Rue Jean Mazen, Dijon, France, 21000
- Phone
- 33 310 451 820
- Website
- oncodesign.com
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers under PROMETHE brand; Nanocyclix, a kinase inhibitors, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
ONCODES.PREC.MED. EO-34 management
5- Dr. Philippe Genne Ph.D.Chairman & CEO
- Ms. Karine LignelChief Operating Officer · born 1970
- Dr. Jan Hoflack Ph.D.Chief Scientific Officer · born 1960
- Mr. Stephane GerartChief Information Officer · born 1983
- Sylvie Fernandes ForsterChief Legal Officer